The Evolution of Self-Reported Urinary and Sexual Dysfunction over the Last Two Decades: Implications for Comparative Effectiveness Research
Matthew J. Resnick(Vanderbilt University Medical Center), David F. Penson(Geriatric Research Education and Clinical Center), Peter C. Albertsen(UConn Health), Richard M. Hoffman(University of Iowa), Tatsuki Koyama(Vanderbilt University Medical Center), Janet L. Stanford, Sherrie H. Kaplan(University of California, Irvine), Dan McCollum(Vanderbilt-Ingram Cancer Center), Antoinette M. Stroup(Rutgers, The State University of New Jersey), Sheldon Greenfield(University of California, Irvine), Alicia K. Morgans(Dana-Farber Cancer Institute), Lisa E. Paddock(Rutgers, The State University of New Jersey), Sharon Phillips(Vanderbilt University Medical Center), Matthew R. Cooperberg(University of California, San Francisco), Ann S. Hamilton(University of Southern California), Karen E. Hoffman(The University of Texas MD Anderson Cancer Center), Xiao‐Cheng Wu(Louisiana State University Health Sciences Center New Orleans), Daniel A. Barocas(Vanderbilt University Medical Center), Michael Goodman(Emory University)
Cited by 17
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Long-Term Functional Outcomes after Treatment for Localized Prostate Cancer
|New England Journal of Medicine|2013|975
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694